Clinical Trial Update: A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety of 0.005% estriol vaginal gel in postmenopausal women with early-stage, hormone receptor–positive breast cancer on aromatase inhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy

Drugs mentioned

• 0.005% estriol vaginal gel (estriol)

Snippet

Sponsor: ITF Research Pharma, S.L.U. | Conditions: Vaginal Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2019-08-05